Foundation of the Massachusetts Eye & Ear Infirmary

The foundation's investment decisions are overseen by its Board of Directors, chaired by Robert Atchinson. The board sets asset-allocation policy and selects external fund managers within a fund-of-funds structure. Day-to-day investment stewardship operates alongside the financial strategy of the parent organization, Mass General Brigham, though the foundation maintains a distinct endowment for the specialty hospital's research and clinical mission.

Since 2018, Mass General Brigham has been the sole corporate member and parent organization of the Foundation and the Mass Eye and Ear hospital system. The hospital itself serves as a primary teaching affiliate for Harvard Medical School's residency programs in ophthalmology and otolaryngology. This governance structure means the foundation's endowment operates under the strategic oversight of one of the largest nonprofit healthcare systems in the United States, while retaining mission-specific fundraising and spending authority for specialty care.

No. The foundation allocates across external managers through a fund-of-funds model and does not take direct equity positions in operating companies. Its investment portfolio includes allocations to growth equity and natural resources strategies, but the foundation is not structured as a venture-capital or direct-investing entity. Philanthropic dollars flow into the endowment, which then funds hospital operations and research grants rather than direct startup investments.

The foundation's capital originates from philanthropic donations directed to Mass Eye and Ear. It operates the Reynolds Society, which recognizes donors who give $2,500 or more annually, and Team Eye and Ear, an athletic fundraising group that raises money through the Boston Marathon and the Falmouth Road Race. The endowment itself grows through investment returns and new gifts, which fund the hospital's clinical programs, surgical volumes, and research at the Schepens Eye Research Institute.

The foundation's investment strategy focuses on fund commitments across growth equity and natural resources, rather than direct investments in specific company stages. This fund-of-funds posture provides diversified exposure to later-stage growth and real assets, aligning with the endowment's need for both capital appreciation and liquidity to support annual hospital operations. The foundation does not operate seed-stage or venture-capital programs internally.

The foundation does not publicly maintain a formal restricted-investment list. However, given its complete alignment with a nonprofit specialty hospital's research and clinical mission, the endowment is not known to pursue strategies in consumer goods, private credit outside its core allocations, or direct real estate development outside its hospital-related property holdings. The investment approach prioritizes diversified external manager relationships over sector-specific direct bets.

The foundation is itself the philanthropic fundraising arm of the hospital — it is not a separate grantmaking entity apart from Mass Eye and Ear. All philanthropic structures, including the Reynolds Society donor recognition program and the Team Eye and Ear athletic fundraising network, feed directly into the foundation's endowment. The investment portfolio and the fundraising operations are managed together as a single financial vehicle supporting the hospital, with no separate private foundation or donor-advised fund program disclosed.